Armesocarb
Armesocarb, also known as -mesocarb or L-mesocarb, is a selective atypical dopamine reuptake inhibitor. It is currently under development for the treatment of Parkinson's disease and sleep disorders.
It is the active -enantiomer of the formerly clinically used stimulant-like drug mesocarb.
Pharmacology
Mesocarb is known to be a highly selective DRI. However, in 2021, it was discovered that mesocarb is not a conventional DRI but acts as a dopamine transporter allosteric modulator or non-competitive inhibitor.In accordance with its nature as an atypical DAT blocker, the drug exhibits atypical effects compared to conventional DRIs. For example, mesocarb shows greater antiparkinsonian activity in animals compared to other DRIs.
Mesocarb has wakefulness-promoting effects in animals. Armesocarb, as the active enantiomer of mesocarb, shows greater therapeutic potency than the racemic form in animals. In contrast, the - or D-enantiomer of mesocarb is virtually inactive in animal behavioral tests.